The Round
Science Corporation has closed a $230 million Series C with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital, among others. Science did not name a lead investor. A source close to the company told TechCrunch the round values Science at $1.5 billion post-money.
The raise brings Science Corp’s total funding to roughly $490 million. The company says the money will fund the commercial launch of PRIMA and its wider research, including a biohybrid neural interface that grows engineered neurons on a device placed on the surface of the brain.
What PRIMA Does
PRIMA is a photovoltaic chip smaller than a grain of rice that is implanted beneath the retina. Paired with camera-equipped smart glasses, the system converts visual information into electrical stimulation patterns that activate remaining retinal neurons, restoring functional vision to patients with advanced age-related macular degeneration (AMD).
In the 38-patient PRIMA trial in Europe, published in the New England Journal of Medicine, 80 percent of patients showed meaningful improvement in visual acuity and were able to read letters, numbers and words.
Path to Market
Science Corp has submitted a CE mark application to European regulators and expects approval by mid-2026. The company says this timeline would make it the first brain-computer interface company with a vision restoration product on the market.
Science told TechCrunch that Germany is likely to be its first market. It has also applied to the FDA for approval in the US, and says its discussions with the agency are ongoing.
Signal: Why it matters
A $1.5 billion valuation signals that investors see brain-computer interfaces moving from research into commerce. The NEJM-published trial gives PRIMA a clinical evidence base that few neural-interface companies can match, and a mid-2026 CE mark would put a Science product on sale in Europe.
For the broader BCI industry, the round shows investors backing vision restoration as a near-term medical device business.
Correction, 17 November 2026: An earlier version of this article said Khosla Ventures and Lightspeed Venture Partners led the round and that it valued Science at about $1.25 billion. Science did not name a lead investor, and TechCrunch corrected its report to a post-money valuation of $1.5 billion. We have also removed a ranking of Science against other brain-implant companies and a US launch timeline that we could not verify, and tied the 80 percent result to the 38-patient trial it came from.